Circle Pharma is a biotechnology company focused on developing innovative macrocyclic peptide therapeutics to address challenging intracellular targets, particularly in oncology. The company operates in the pharmaceutical and biotechnology market, serving clients such as pharmaceutical companies and research institutions. Circle Pharma's business model revolves around its proprietary discovery engine, which combines computational structure-based design with automated synthetic chemistry to create cell-permeable macrocycles. These macrocycles are designed to target protein-protein interactions that are critical in cancer but have been difficult to address with traditional small molecule drugs. The company generates revenue through collaborations, partnerships, and licensing agreements with major pharmaceutical companies. Circle Pharma's approach leverages advanced computational techniques to screen large virtual libraries of macrocycles, ensuring high target affinity and cell permeability. This innovative method allows the company to develop therapeutics with significant clinical and commercial potential.

Keywords: macrocyclic peptides, oncology, intracellular targets, computational design, synthetic chemistry, protein-protein interactions, biotechnology, pharmaceutical, cell permeability, drug discovery.